John N. Allan

John N. Allan, M.D., is an Associate Professor of Clinical Medicine at Weill Cornell Medical College, Cornell University, and an Associate Attending Physician at NewYork-Presbyterian Hospital. His clinical expertise spans Chronic Lymphocytic Leukemia (CLL), Lymphoma, and Immunotherapy, with a focus on Richter’s Syndrome and novel targeted therapies.

• Education: M.D. from St. Louis University School of Medicine (2009), B.S. in Biochemistry and Finance from the University of Missouri-Columbia (2003)

Dr. Allan’s research investigates genomic and metabolic drivers of CLL and Richter’s Syndrome, including the role of mutations (e.g., NOTCH1, BTK), drug resistance mechanisms, and bispecific antibodies. His 15 most recent publications (2025–2022) cover real-world treatment outcomes, novel therapeutic combinations (ibrutinib, venetoclax), and molecular profiling of lymphoid malignancies.

Scientific awards include induction into Alpha Sigma Nu (2002), Alpha Omega Alpha (2008), Arnold P. Gold Humanism in Medicine (2009), and the Susan Murphy Fellowship Award (2014). He has collaborated with organizations such as AbbVie, BeiGene, and NeoGenomics Laboratories.

His work integrates clinical trials and translational research, with a focus on improving survival and individualized care in hematologic cancers.